Sydney Jennings

Your daily dose of the clinical news you may have missed.

The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.

Comments on the draft recommendation can be submitted through December 23, 2024.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The recommendations from WikiGuidelines are the first for UTI prevention, diagnosis, and management in over a decade.

Your daily dose of the clinical news you may have missed.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

The target action date for the FDA decision is April 18, 2025, according to Sanofi and Regeneron.

Your daily dose of the clinical news you may have missed.

The CDC just released its annual STD surveillance report. Are you caught up on the latest trends? Try your hand at these 7 questions to find out.

Your daily dose of the clinical news you may have missed.

More than 2.4 million STIs were reported in the US in 2023 — a 1.8% decrease from 2022, according to the CDC's annual STI report.

Your daily dose of the clinical news you may have missed.

The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.

Your daily dose of the clinical news you may have missed.

Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.

Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.

Your daily dose of the clinical news you may have missed.

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.